Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India's Medanta promises step-change in hi-tech access with Siemens contract

This article was originally published in Clinica

Executive Summary

Under what is being billed as one of India's largest private healthcare industry contracts, Siemens is introducing to the country a range of its scanning and cathlab systems for the first time. The imaging and IT systems partnership with Medanta-The Medicity, in Gurgaon (Haryana state), a satellite city of New Delhi, will see the launch of the Somatom Definition Flash CT scanner, the Artis Zeego cathlab, Acuson SC2000 ultrasound system and the PET/CT scanner Biograph mCT. The Medanta complex, which features 300 critical beds, 45 operating theatres and a research centre, is promising to offer the "range of first-of-its-kind technology while providing care at an affordable cost". Siemens in India has reported an annual business volume of Rs11,800 crore (US$2.44bn), at September 2008.

You may also be interested in...



Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar

Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT044029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel